250 related articles for article (PubMed ID: 21248225)
1. Mutant proteins as cancer-specific biomarkers.
Wang Q; Chaerkady R; Wu J; Hwang HJ; Papadopoulos N; Kopelovich L; Maitra A; Matthaei H; Eshleman JR; Hruban RH; Kinzler KW; Pandey A; Vogelstein B
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2444-9. PubMed ID: 21248225
[TBL] [Abstract][Full Text] [Related]
2. An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity.
Ruppen-Cañás I; López-Casas PP; García F; Ximénez-Embún P; Muñoz M; Morelli MP; Real FX; Serna A; Hidalgo M; Ashman K
Proteomics; 2012 May; 12(9):1319-27. PubMed ID: 22589181
[TBL] [Abstract][Full Text] [Related]
3. Targeted data-independent acquisition for mass spectrometric detection of RAS mutations in formalin-fixed, paraffin-embedded tumor biopsies.
Kim YJ; Chambers AG; Cecchi F; Hembrough T
J Proteomics; 2018 Oct; 189():91-96. PubMed ID: 29684684
[TBL] [Abstract][Full Text] [Related]
4. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Fang B
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):27-38. PubMed ID: 26350096
[TBL] [Abstract][Full Text] [Related]
5. GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples.
Halvey PJ; Ferrone CR; Liebler DC
J Proteome Res; 2012 Jul; 11(7):3908-13. PubMed ID: 22671702
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
Adackapara CA; Sholl LM; Barletta JA; Hornick JL
Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
Jing J; Greshock J; Holbrook JD; Gilmartin A; Zhang X; McNeil E; Conway T; Moy C; Laquerre S; Bachman K; Wooster R; Degenhardt Y
Mol Cancer Ther; 2012 Mar; 11(3):720-9. PubMed ID: 22169769
[TBL] [Abstract][Full Text] [Related]
8. Molecular beacon imaging of tumor marker gene expression in pancreatic cancer cells.
Yang L; Cao Z; Lin Y; Wood WC; Staley CA
Cancer Biol Ther; 2005 May; 4(5):561-70. PubMed ID: 15917666
[TBL] [Abstract][Full Text] [Related]
9. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
10. Identification and selective degradation of neopeptide-containing truncated mutant proteins in the tumors with high microsatellite instability.
Kim WK; Park M; Park M; Kim YJ; Shin N; Kim HK; You KT; Kim H
Clin Cancer Res; 2013 Jul; 19(13):3369-82. PubMed ID: 23674496
[TBL] [Abstract][Full Text] [Related]
11. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.
Guinney J; Ferté C; Dry J; McEwen R; Manceau G; Kao KJ; Chang KM; Bendtsen C; Hudson K; Huang E; Dougherty B; Ducreux M; Soria JC; Friend S; Derry J; Laurent-Puig P
Clin Cancer Res; 2014 Jan; 20(1):265-272. PubMed ID: 24170544
[TBL] [Abstract][Full Text] [Related]
12. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibodies targeting mutant
Douglass J; Hsiue EH; Mog BJ; Hwang MS; DiNapoli SR; Pearlman AH; Miller MS; Wright KM; Azurmendi PA; Wang Q; Paul S; Schaefer A; Skora AD; Molin MD; Konig MF; Liu Q; Watson E; Li Y; Murphy MB; Pardoll DM; Bettegowda C; Papadopoulos N; Gabelli SB; Kinzler KW; Vogelstein B; Zhou S
Sci Immunol; 2021 Mar; 6(57):. PubMed ID: 33649101
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.
Duan YF; Li DF; Liu YH; Mei P; Qin YX; Li LF; Lin QX; Li ZJ
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):204-9. PubMed ID: 23558076
[TBL] [Abstract][Full Text] [Related]
15. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers.
Stalnecker CA; Der CJ
Sci Signal; 2020 Mar; 13(624):. PubMed ID: 32209699
[TBL] [Abstract][Full Text] [Related]
16. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG
Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
Schönleben F; Qiu W; Allendorf JD; Chabot JA; Remotti HE; Su GH
J Gastrointest Surg; 2009 Aug; 13(8):1510-6. PubMed ID: 19440799
[TBL] [Abstract][Full Text] [Related]
19. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
[TBL] [Abstract][Full Text] [Related]
20. Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer.
Wiesweg M; Kasper S; Worm K; Herold T; Reis H; Sara L; Metzenmacher M; Abendroth A; Darwiche K; Aigner C; Wedemeyer HH; Helfritz FA; Stuschke M; Schumacher B; Markus P; Paul A; Rahmann S; Schmid KW; Schuler M
Oncogene; 2019 Apr; 38(16):2953-2966. PubMed ID: 30568222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
